Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

NCT01004822

Advanced Solid Tumors

TERMINATED PHASE1

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

NCT00879554

Advanced Solid Tumors Neoplasms Carcinoma +2 more

COMPLETED PHASE1

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757

Advanced Solid Tumors Cancer

COMPLETED PHASE1

Study of PYX-201 in Solid Tumors

NCT05720117

Solid Tumor Advanced Solid Tumor

RECRUITING PHASE1

Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

NCT01313065

Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors Neoplasms Carcinoma Cancer Malignancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

CVX-060

Intervention Type BIOLOGICAL

Weekly, intravenous dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CVX-060

Weekly, intravenous dose

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
* Adequate coagulation, liver, and renal function.
* Candidate for DCE-MRI evaluations.
* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

Exclusion Criteria

* Evidence of significant bleeding problems.
* History of certain gastrointestinal problems including fistula and abscess.
* Chronic, uncontrolled hypertension.
* Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No